Diligence memo · auto-generated · as of July 2, 2026
Proximity Therapeutics, Inc.
Proximity Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Proximity Therapeutics, Inc. operates in Biotechnology, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Proximity Therapeutics, Inc. has raised $11M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2021-05-04.
Most recent recorded round closed around 2021-05-04.
Valuation (modeled)modeled
Provath models Proximity Therapeutics, Inc. at approximately $265M (range $12M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.47× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era. Within the normal band (147% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5.2 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 58% of Biotechnology peers (4293 compared).
Modeled value ranks above 75% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.